nach oben

Acta Neuropathologica

Erschienen in:

01.10.2003 | Regular Paper

Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study

verfasst von: Yoshinobu Wakisaka, Akiko Furuta, Yumihiro Tanizaki, Yutaka Kiyohara, Mitsuo Iida, Toru Iwaki

Erschienen in: Acta Neuropathologica | Ausgabe 4/2003

Einloggen, um Zugang zu erhalten

Abstract

In dementia with Lewy bodies (DLB), the Lewy bodies (LBs) are an essential substrate. Although LB pathology has gained increasing attention as one of the major causes of dementia, little is known about the exact prevalence of LB pathology in the general population. In addition, the pathology of Alzheimer-type dementia (ATD) is frequently associated with DLB. To investigate the prevalence of LB pathology in a community-based population and to evaluate the relationship between LB and ATD pathology, we performed an analysis of 102 consecutive autopsy cases. The survey extended over 2.5 years and autopsy rate was 70.5%. LB pathology was detected using α-synuclein immunohistochemistry and was assessed based on consensus guidelines for DLB. ATD pathology was evaluated by both CERAD and NIA-RI criteria. Twenty-nine subjects were clinically demented. LB pathology was present in 23 (22.5%) of 102 cases, and in 12 (41.4%) of the demented subjects. The LB score was not significantly different between DLB cases and non-demented subjects with LB pathology (nd-LB), while the Braak stages were significantly different between the two groups. Prevalence of LB pathology constantly increased with age. DLB cases accompanying severe ATD pathology showed more rapid increase of LB scores than did DLB cases without severe ATD pathology. Moreover, DLB cases with severe ATD pathology had poorer prognoses than those without severe ATD pathology. Our results suggested that aging and severe ATD pathology have a strong effect on the evolution of LB pathology.

American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. American Psychiatric Association, Washington, DC

Anonymous (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The national institute on aging, and Reagan institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging 18: S1–S2

Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical distribution of neurofibrillary tangles and neuritic plaque in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1:103–116PubMed

Baba H, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152:879–884PubMed

Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMed

Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58:376–388PubMed

Del Tredici K, Rüb U, Vos RAI de, Bohl JRE, Braak H (2002) Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413–426

Gibb WR, Less AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51:745–752PubMed

Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT (1999) Clinical and quantitative pathological correlates of dementia with Lewy bodies. Neurology 53:1284–1291PubMed

10.

Hamilton RL (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 10:378–394PubMed

11.

Hansen LA, Masliah E, Galasko D, Terry RD (1993) Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. J Neuropathol Exp Neurol 52:648–654PubMed

12.

Haroutunian V, Serby M, Purohit DP, Perl DP, Marin D, Lantz M, Mohs RC, Davis KL (2000) Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 57:1145–1150PubMed

13.

Heyman A, Fillenbaum GG, Gearing M, Mirra SS, Welsh-Bohmer KA, Peterson B, Pieper C (1999) Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer' disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX. Neurology 52:1839–1844PubMed

14.

Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50:140–148PubMed

15.

Ince PG, McArthur FK, Bjertness E, Torvik A, Candy JM, Edwardson JA (1995) Neuropathological diagnosis in elderly patients in Oslo: Alzheimer's disease, Lewy body disease, vascular lesions. Dementia 6:162–168PubMed

16.

Ince PG, Perry EK, Morris CM (1998) Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol 8:299–324

17.

Iwatubo T, Yamaguchi H, Fujimuro M, Yokosawa H, Ihara Y, Trojanowski JQ, Lee VMY (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol 148:1517–1529

18.

Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109:329–339PubMed

19.

Katsuki S (1966) Epidemiological and clinicopathological study on cerebrovascular disease in Japan. Prog Brain Res 21B: 64–89

20.

Kawashima M, Suzuki SO, Doh-ura K, Iwaki T (2000) α-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation. Acta Neuropathol 99:154–160PubMed

21.

Kiyohara Y, Yoshitake T, Kato I, Ohmura T, Kawano H, Ueda K, Fujishima M (1994) Changing patterns in the prevalence of dementia in a Japanese community: the Hisayama study. Gerontology 40 (Suppl 2): 29–35PubMed

22.

Kosaka K, Iseki E (2000) Clinicopathological studies on diffuse Lewy body disease. Neuropathology 20:1–7CrossRefPubMed

23.

Lindboe CF, Hansen HB (1998) The frequency of Lewy bodies in a consecutive autopsy series. Clin Neuropathol 17:204–209PubMed

24.

Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O'Connell B, Pollen DA, St. George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ (1998) Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365–1370PubMed

25.

Lopez OL, Becker JT, Kaufer DI, Hamilton RL, Sweet RA, Klunk W, DeKosky ST (2002) Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 59:43–46CrossRefPubMed

26.

McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, Vos RA de, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB); report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMed

27.

McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop. Diagnosis and treatment. Neurology 53:902–905PubMed

28.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939–944PubMed

29.

Mirra SS, Heyman A, Mckeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479–486PubMed

30.

Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357:169–175PubMed

31.

Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ (1998) Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 51:351–357PubMed

32.

Parkkinen L, Soininen H, Laakso M, Alafuzoff I (2001) α-Synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27:314–325CrossRefPubMed

33.

Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 62:363–367PubMed

34.

Perry RH, Irving D, Tomlinson BE (1990) Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 100:223–233CrossRefPubMed

35.

Rinne JO, Rummukainen J, Paljärvi L, Rinne UK (1989) Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26:47–50

36.

Román GC, Tatemichi TK, Erkinjuntti T, et al (1993) Vascular dementia: diagnostic criteria for research stusies. Report of the NINDS-AIREN International Workshop. Neurology 43:250–260PubMed

37.

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) α-Synuclein in Lewy bodies. Nature 388:839–840PubMed

38.

Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, Fujishima M (2000) Incidence and risk factors for subtypes of cerebral infarction in a general population. The Hisayama study. Stroke 31:2616–2622PubMed

39.

Van Duinen SG, Lammers GJ, Maat-Schieman MLC, Ross RAC (1999) Numerous and widespread α-synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neurol 97:533–539CrossRef

40.

Yamazaki M, Arai Y, Baba M, Iwatsubo T, Mori O, Katayama Y, Oyanagi K (2000) α-Synuclein inclusions in amygdala in the brains of patiens with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 59:585–3591PubMed

41.

Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K, Sueishi K, Tsuneyoshi M, Fujishima M (1995) Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama study. Neurology 45:1161–1168PubMed

Titel: Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study
verfasst von: Yoshinobu Wakisaka
Akiko Furuta
Yumihiro Tanizaki
Yutaka Kiyohara
Mitsuo Iida
Toru Iwaki
Publikationsdatum: 01.10.2003
Verlag: Springer-Verlag
Erschienen in: Acta Neuropathologica / Ausgabe 4/2003
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-003-0750-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2003

The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy